Advertisement

Topics

Sangamo to transfer two gene therapies to Biogen spin-off

03:53 EST 1 Dec 2016 | BioPharmaDive

Adding the hemoglobinopathy programs, which Sangamo had partnered with Biogen on, will bolster the fledgling Bioverativ's pipeline in rare blood disorders. 

Original Article: Sangamo to transfer two gene therapies to Biogen spin-off

NEXT ARTICLE

More From BioPortfolio on "Sangamo to transfer two gene therapies to Biogen spin-off"

Quick Search
Advertisement